Retesting TB-500: following up on last cycle's discrepancies
Purity across our TB-500 samples ranged from 97.4% to 99.7%. Here is the context.
The Peptide Institute Testing Desk··12 min read
TB-500 is a synthetic thymosin beta-4 derivative with a development status of "preclinical". The Institute rates the strength of its published evidence as emerging. A synthetic version of a naturally occurring actin-binding peptide studied in models of tissue repair, cell migration, and cardiac injury.
This report covers the TB-500 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 7 TB-500 samples from 6 companies. 100% met their label claims on purity and content. Measured purity ranged from 97.4% to 99.7%, averaging 98.3%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
The two halves of the Wolverine stack just won a big vote from an FDA advisory committee. Here is what happened, why it matters, and the White House review that could come next.
Healing often recruits new blood-vessel growth. Tumors can use related pathways. Here is the pattern literacy behind “repair peptide” talk, without turning BPC-style names into a protocol.
Purity across our Semaglutide samples ranged from 58.1% to 99.1%. Here is the context.
Testing Report
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
